A newly published study concludes that the MammaPrint® breast cancer test can accurately stratify a woman's breast cancer risk for up to 25 years after she is first diagnosed with the disease. U.S. and Dutch researchers reported the longest-term follow-up study of its kind that confirms the durable accuracy of a unique genomic test for early-stage breast cancer.

More...